IP Library › Granted Patent US 12,419,940
Granted Patent B2
US 12,419,940 · App. 17/198,037 · Granted Sep 23, 2025

Compositions and methods for modified dendrimer nanoparticle delivery

Inventors: Omar F. Khan (Cambridge, MA); Jasdave S. Chahal (Arlington, MA); Daniel G. Anderson (Cambridge, MA); Hidde Ploegh (Brookline, MA); Robert S. Langer (Cambridge, MA); Tyler E. Jacks (Cambridge, MA); David A. Canner (Cambridge, MA)
Assignees: Massachusetts Institute of Technology; Whitehead Institute For Biomedical Research
A61K39/0012A61K9/0019A61K9/5146A61K31/713A61K39/002A61K39/12A61K39/145A61K48/00C12N15/87C12N15/88A61K2039/53A61K2039/645A61K2039/70C12N2740/16234C12N2760/14134C12N2760/16034C12N2770/24134C12N2770/36143Y02A50/30
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,419,940
App. No.
17/198,037
Granted
Sep 23, 2025
Kind
B2
Abstract

Compositions and methods for modified dendrimer nanoparticle (“MDNP”) delivery of therapeutic, prophylactic and/or diagnostic agent such as large repRNA molecules to the cells of a subject have been developed. MDNPs efficiently drive proliferation of antigen-specific T cells against intracellular antigen, and potentiate antigen-specific antibody responses. MDNPs can be multiplexed to deliver two or more different repRNAs to modify expression kinetics of encoded antigens and to simultaneous deliver repRNAs and mRNAs including the same UTR elements that promote expression of encoded antigens.

Claims (29)

1. A method for delivering a therapeutic, prophylactic and/or diagnostic agent to a subject, comprising administering to the subject a modified dendrimer nanoparticle comprising

(i) one or more dendrimers selected from the group consisting of one to seven generation poly(ethylene imine) dendrimers and two to seven generation poly(propylene imine) dendrimers;

(ii) one or more amphiphilic polymers, wherein the amphiphilic polymer is 1,2-dimystistoyl-sn-glycerol-3-phosphoethanolamine-N-[methoxy (polyethylene glycol)-2000]

wherein the amphiphilic polymer is not a dendrimer; and

(iii) one or more nucleic acids that express or encode one or more therapeutic, prophylactic and/or diagnostic agents;

wherein the nucleic acids are encapsulated in the dendrimer nanoparticle wherein the nanoparticle does not include cholesterol.

2. The method of claim 1 , wherein the nanoparticle delivers one or more replicating RNAs, and wherein the replicating RNAs express one or more proteins in the cells of a subject.

3. The method of claim 2 , wherein the one or more replicating RNAs express two or more proteins in the cells of the subject, and wherein the replicating RNAs express the proteins at different rates.

4. The method of claim 1 , wherein the one or more dendrimers is poly(ethyleneimine).

5. The method of claim 4 , wherein the one or more dendrimers is polypropylene imine.

6. The method of claim 1 , wherein the one or more dendrimers is modified by the addition of epoxide-terminated alkyl chains, in a size between 1 and 30 carbons, inclusive.

7. The method of claim 1 , wherein the amphiphilic polymer comprises a hydrophilic component selected from the group consisting of polyalkylene oxides and block copolymers thereof.

8. The method of claim 1 , wherein the amphiphilic polymer comprises a hydrophobic component selected from the group consisting of a lipid and a phospholipid.

9. The method of claim 7 , wherein the mass ratio of dendrimer to hydrophilic component of the amphiphilic polymer is between 20:1 and 5:1.

10. The method of claim 1 , wherein the nanoparticle further comprises a therapeutic, prophylactic, and/or diagnostic agent selected from the group consisting of proteins, peptides, carbohydrates, nucleic acids, lipids, drugs, and combinations thereof.

11. The method of claim 10 , wherein the nucleic acids are selected from the group consisting of complementary DNA (cDNA), replicating RNA (repRNA), messenger RNA (mRNA), small interfering RNA (siRNA), transfer RNA (tRNA), guide-strand RNA (sgRNA), microRNA (miRNA), double-stranded RNA (dsRNA) that is at least 24 nucleotides in length, and combinations thereof.

12. The method of claim 11 , wherein the nucleic acids comprise one or more ribonucleic acid sequences of between approximately 10 and 20,000 bases in length, inclusive.

13. The method of claim 12 , wherein the mass ratio of dendrimer to ribonucleic acid is between 10:1 and 1.5:1 inclusive.

14. The method of claim 12 , wherein the replicating RNA comprises a modified alphavirus replicon RNA.

15. The method of claim 1 , wherein the nanoparticle comprises two or more replicating RNAs, wherein the replicating RNAs independently encode one or more antigens from an infectious agent, parasite, or abnormal proliferation disorder such as cancer.

16. The method of claim 11 , wherein the nanoparticle comprises one or more replicating RNAs and one or more messenger RNAs, and wherein the messenger RNA is modified to include the 5′ and 3′ untranslated regions of the replicating RNA.

17. The method of claim 1 , wherein the size of the nanoparticle is between 30 nm and 450 nm, inclusive.

18. The method of claim 6 , wherein the epoxide-terminated alkyl chains are between 6 and 16 carbons, inclusive.

19. The method of claim 9 , wherein the mass ratio of the one or more dendrimers to hydrophilic component of the amphiphilic polymer is 11.5:1.

20. The method of claim 12 , wherein the ribonucleic acid sequences are between approximately 9,000 and 15,000 bases in length, inclusive.

21. The method of claim 13 , wherein the mass ratio of the one or more dendrimers to ribonucleic acid is 5:1.

22. The method of claim 17 , wherein the size of the nanoparticle is between 60 nm and 250 nm in diameter, inclusive.

23. The method of claim 1 , wherein alkylated dendrimer consists of poly(ethyleneimine), and

wherein the nucleic acid consists of replicating RNA.

Assignments (5)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 7, 2021
From: KHAN, OMAR F.; ANDERSON, DANIEL G.; LANGER, ROBERT S.
To: MASSACHUSETTS INSTITUTE OF TECHNOLOGY
Reel/Frame 056451/0654 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 7, 2021
From: JACKS, TYLER E.
To: HOWARD HUGHES MEDICAL INSTITUTE
Reel/Frame 056451/0794 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 7, 2021
From: HOWARD HUGHES MEDICAL INSTITUTE
To: MASSACHUSETTS INSTITUTE OF TECHNOLOGY
Reel/Frame 056451/0890 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 7, 2021
From: CANNER, DAVID A.
To: MASSACHUSETTS INSTITUTE OF TECHNOLOGY
Reel/Frame 056451/0911 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 7, 2021
From: CHAHAL, JASDAVE S.; PLOEGH, HIDDE
To: WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH
Reel/Frame 056451/0939 →
Continuity (4)
Continuation 16692624 · Nov 22, 2019
Division 15274954 · Sep 23, 2016
Provisional Application 62222515 · Sep 23, 2015
Related Publication 20210338789A1 · Nov 4, 2021
References Cited (93)
US 5714166A · Tomalia · 1998 [cited by applicant]
US 20080114077A1 · Yin · 2008 [cited by applicant]
US 20140255472A1 · Geall · 2014 [cited by applicant]
US 20150366997A1 · Guild · 2015 [cited by applicant]
WO 2006040579 · 2006 [cited by applicant]
Al-Dosari, et al., “Nonviral gene delivery: principle, limitations, and recent progress”, AAPS J. 11:671-81 (2009). [cited by applicant]
Atkins, et al., “Therapeutic and prophylactic applications of alphavirus vectors”, Expert Rev Mol Med, 10: e33 (2008). [cited by applicant]
Baum and Garcia-Sastre, “Induction of type I interferon by RNA viruses: cellular receptors and their substrates”, Amino Acids, 38(5):1283-99 (2010). [cited by applicant]
Bernstein, et al., “Role for a bidentate ribonuclease in the initiation step of RNA interference”, Nature, 409:363-6 (2001). [cited by applicant]
Bhadury, et al., “Identification of tumorigenic and therapeutically actionable mutations in transplantable mouse tumor cells by exome sequencing”, Oncogenesis, 2(e44):1-5 (2013). [cited by applicant]
Biswas, et al., “Dendrimers for siRNA delivery”, Pharmaceuticals, 6:161-83 (2013). [cited by applicant]
Bogers, et al., “Potent immune responses in rhesus macaques induced by nonviral delivery of a self-amplifying RNA vaccine expressing HIV type 1 envelope with a cationic nanoemulsion”, J Infect Dis., 211(6):947-55(2015). [cited by applicant]
Brito, et al., “A cationic nanoemulsion for the delivery of next-generation RNA vaccines”, Mol Ther., 22(12):2118-29 (2014). [cited by applicant]
Cho, “Design and development of degradable polyethylenimines for delivery of DNA and small interfering RNA: An updated review”, ISRN Mats Sci,, 2(16):2903-24 (2012). [cited by applicant]
Cong, et al., “Multiplex genome engineering using CRISPR/Cas systems”, Science, 339:819-23 (2013). [cited by applicant]
Conti, et al., “Poly(amidoamine) dendrimer nanocarriers and their aerosol formulations for siRNA delivery to the lung epithelium”, Mol. Pharmaceutics, 11:1808-22 (2014). [cited by applicant]
Cullis, et al., “Interactions of liposomes and lipid-based carrier systems with blood proteins: Relation to clearance behaviour in vivo”, Adv Drug Deliv Rev., 32(1-2):3-17 (1998). [cited by applicant]
Dougan, et al., “Antigen-specific B-cell receptor sensitizes B cells to infection by influenza virus”, Nature 503(7476):406-409 (2013). [cited by applicant]
Elbashir, et al., “Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells”, Nature, 411:494-8 (2001b). [cited by applicant]
Elbashir, et al., “RNA interference is mediated by 21- and 22-nucleotide RNAs”, Genes Dev., 15:188-200 (2001a). [cited by applicant]
Felgner, et al., “Enhanced gene delivery and mechanism studies with a novel series of cationic lipid formulations”, J. Biol. Chem., 269:2550-61 (1994). [cited by applicant]
Fire, et al., “Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans”, Nature, 391:806-11 (1998). [cited by applicant]
Fuchs, et al., “First-in-Human Evaluation of the Safety and Immunogenicity of a Recombinant Vesicular Stomatitis Virus Human Immunodeficiency Virus-1 gag Vaccine (HVTN 090).”, Open Forum Infect Dis., 2:1-9 (2015). [cited by applicant]
Gao, et al., “The association of autophagy with polyethylenimine-induced cytotoxicity in nephritic and hepatic cell lines”, Biomaterials, 32:8613-25 (2011). [cited by applicant]
Geall, et al., “Nonviral delivery of self-amplifying RNA vaccines”, PNAS, 109(36):14604-9 (2012). [cited by applicant]
Gupta, et al., “Adjuvants—a balance between toxicity and adjuvanticity”, Vaccine, 11(3):293-306 (1993). [cited by applicant]
Hammond, et al., “An RNA-directed nuclease mediates post-transcriptional gene silencing in [cited by applicant]
Hannon, “RNA interference”, Nature, 418:244-51 ( 2002). [cited by applicant]
Heil, et al., “Species-specific recognition of single-stranded RNA via toll-like receptor 7 and 8”, Science, 303(5663):1526-9 (2004). [cited by applicant]
Hekele, et al., “Rapidly produced SAM(®) vaccine against H7N9 influenza is immunogenic in mice”, Emerg Microbes Infect 2(e52):1-7 (2013). [cited by applicant]
Henriksen-Lacey, et al., “Comparison of the depot effect and immunogenicity of liposomes based on dimethyldioctadecylammonium (DDA), 3ß-[N-(N′,N′-Dimethylaminoethane)carbomyl] cholesterol (DC-Chol), and 1,2-Dioleoyl-3-r… [cited by applicant]
Hoerr, et al., “In vivo application of RNA leads to induction of specific cytotoxic T lymphocytes and antibodies”, Eur J Immunol, 30(1):1-7 (2000). [cited by applicant]
Hoffmann, et al., “Annual cost of illness and quality-adjusted life year losses in the United States due to 14 foodborne pathogens”, J Food Prot., 75(7):1292-302 (2012). [cited by applicant]
Hofland, et al., “Formation of stable cationic lipid/DNA complexes for gene transfer”, PNAS, 93(14):7305-9 (1996). [cited by applicant]
International Search report and Written Opinion for corresponding PCT application PCT/US2016/053520 mailed Jan. 4, 2017. [cited by applicant]
Jinek, et al., “A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity”, Science, 337(6096):816-21 (2012). [cited by applicant]
Kafil, et al., “Cytotoxic impacts of linear and branched polyethylenimine nanostructures in a431 cell”, Biolmpacts, 1(1):23-30 (2011). [cited by applicant]
Kariko, et al., “mRNA is an endogenous ligand for Toll-like receptor 3”, J Biol Chem, 279(13):12542-50 (2004). [cited by applicant]
Khan, et al., “Dendrimer-Inspired Nanomaterials for the in Vivo Delivery of siRNA to Lung Vasculature”, Nano Lett 15(5):3008-16 (2015). [cited by applicant]
Khan, et al., “lonizable amphiphilic dendrimer-based nanomaterials with alkyl-chain-substituted amines for tunable siRNA delivery to the liver endothelium in vivo”, Angew Chemie, 53(52):14397-401 (2014). [cited by applicant]
Khromykh, “Replicon-based vectors of positive strand RNA viruses”, Curr Opin Mol Ther, 2:555-69 (2000). [cited by applicant]
Kofler, et al.,“Mimicking live flavivirus immunization with a noninfectious RNA vaccine”, PNAS, 101:1951-6 (2004). [cited by applicant]
Kreiter, et al., “Intranodal vaccination with naked antigen-encoding RNA elicits potent prophylactic and therapeutic antitumoral immunity”, Cancer Res, 70(22):9031-9040 (2010). [cited by applicant]
Kreiter, et al., “Tumor vaccination using messenger RNA: prospects of a future therapy”, Curr Opin Immunol, 23(3):399-406 (2011). [cited by applicant]
Kuhn, et al., “Virus nomenclature below the species level: a standardized nomenclature for laboratory animal-adapted strains and variants of viruses assigned to the family Filoviridae”, Arch Virol, 158(6):1425-32 (2013). [cited by applicant]
Levin, et al., “Characterization of purified double-stranded RNA-activated elF-2 alpha kinase from rabbit reticulocytes”, J Biol Chem, 256(14):7638-41 (1981). [cited by applicant]
Li, et al., “Characterization of cationic lipid-protamine-DNA (LPD) complexes for intravenous gene delivery”, Gene Ther., 5:930-7 (1998). [cited by applicant]
Liljestrom and Garoff, “A new generation of animal cell expression vectors based on the Semliki Forest virus replicon”, Biotechnology, 9(12):1356-61 (1991). [cited by applicant]
Lopez-Gordo, et al., “Circumventing antivector immunity: potential use of nonhuman adenoviral vectors”, Hum Gene Ther., 25(4):285-300 (2014). [cited by applicant]
Lundstrom, “Alphavirus-based vaccines”, Curr Opin Mol Ther, 4:28-34 (2002). [cited by applicant]
Lundstrom, “Alphaviruses in gene therapy”, Viruses, 7(5):2321-33 (2015). [cited by applicant]
Lv, et al., “Toxicity of cationic lipids and cationic polymers in gene delivery”, J. Control. Release, 114(1):100-9 (2006). [cited by applicant]
Martinez, et al., “Single-stranded antisense siRNAs guide target RNA cleavage in RNAi”, Cell, 110:563-74 (2002). [cited by applicant]
McCullough, et al., “Self-Amplifying Replicon RNA Vaccine Delivery to Dendritic Cells by Synthetic Nanoparticles”, Vaccines, 2:735-54 (2014b). [cited by applicant]
McCullough, et al., “Self-replicating Replicon-RNA Delivery to Dendritic Cells by Chitosan-nanoparticles for Translation In Vitro and In Vivo”, Mol Ther-Nucleic Acids, 3(e173):1-17 (2014a). [cited by applicant]
Mirska, et al., “Biophysical and biochemical properties of a binary lipid mixture for DNA transfection”, Colloids Surf B Biointerfaces, 40(1):51-9 (2005). [cited by applicant]
Mockey, et al., “mRNA-based cancer vaccine: prevention of B16 melanoma progression and metastasis by systemic injection of MART1 mRNA histidylated lipopolyplexes”, Cancer Gene Ther., 14(9):802-14 (2007). [cited by applicant]
Napoli, et al., Introduction of a Chimeric Chalcone Synthase Gene into Petunia Results in Reversible Co-Suppression of Homologous Genes in trans., Plant Cell, 2(4):279-289 (1990). [cited by applicant]
Nykanen, et al., “ATP requirements and small interfering RNA structure in the RNA interference pathway”, Cell, 107:309-21 (2001). [cited by applicant]
Partridge, et al., “Global production of seasonal and pandemic (H1N1) influenza vaccines in 2009-2010 and comparison with previous estimates and global action plan targets”, Vaccine 28(30):4709-12 (2010). [cited by applicant]
Petsch, et al., “Protective efficacy of in vitro synthesized, specific mRNA vaccines against influenza A virus infection”, Nat Biotechnol, 30:1210-6 (2012). [cited by applicant]
Phua, et al., “Intranasal mRNA nanoparticle vaccination induces prophylactic and therapeutic anti-tumor immunity”, Sci Rep, 4(5128):1-7 (2014). [cited by applicant]
Pichlmair, et al., “RIG-I-mediated antiviral responses to single-stranded RNA bearing 5′-phosphates”, Science, 314(5801):997-1001 (2006). [cited by applicant]
Pollard, et al., “Type | IFN counteracts the induction of antigen-specific immune responses by lipid-based delivery of mRNA vaccines”, Mol Ther, 21(1):251-9 (2013). [cited by applicant]
Rayner, et al., “Alphavirus vectors and vaccination”, Rev Med Virol., 12:279-96 (2002). [cited by applicant]
Rittig, et al., “Intradermal vaccinations with RNA coding for TAA generate CD8+ and CD4+ immune responses and induce clinical benefit in vaccinated patients”, Mol Ther., 19(5):990-9 (2011). [cited by applicant]
Sahin, et al., “mRNA-based therapeutics developing a new class of drugs”, Nature Rev., 13(10):759-80 (2014). [cited by applicant]
Schijns, et al., “Trends in vaccine adjuvants”, Expert Rev Vaccines, 10(4):539-50 (2011). [cited by applicant]
Sledz and Williams, “RNA interference in biology and disease”, Blood, 106(3):787-94 (2005). [cited by applicant]
Small, et al., “Viruses—from pathogens to vaccine carriers”, Curr Opin Virol., 1(4):241-5 (2011). [cited by applicant]
Srivastava, et al., “Gene vaccines”, Ann Intern Med., 138(7):550-9 (2003). [cited by applicant]
Tros de Ilarduya, et al., “Gene delivery by lipoplexes and polyplexes”, Eur. J. Pharm. Sci., 40:159-70 (2010). [cited by applicant]
Ui-Tei, et al., “Sensitive assay of RNA interference in [cited by applicant]
Ulmer, et al., “RNA-based vaccines”, Vaccine, 30(30):4414-8 (2012). [cited by applicant]
Van Lint, et al., “Preclinical evaluation of TriMix and antigen mRNA-based antitumor therapy”, Cancer Res, 72:1661-71 (2012). [cited by applicant]
Van Lint, et al., “The ReNAissance of mRNA-based cancer therapy”, Expert Rev Vaccines, 14(2):235-251 (2015). [cited by applicant]
Wang, et al., “Non-viral gene delivery methods”, Curr Pharma Biotech., 14:46-60 (2013). [cited by applicant]
Warren, et al., “Highly efficient reprogramming to pluripotency and directed differentiation of human cells with synthetic modified mRNA”, Cell Stem Cell, 7:618-30 (2010). [cited by applicant]
Weide, et al., “Direct injection of protamine-protected mRNA: results of a phase 1/2 vaccination trial in metastatic melanoma patients”, J Immunother, 32(5):498-507 (2009). [cited by applicant]
Weide, et al., “Results of the first phase I/II clinical vaccination trial with direct injection of mRNA”, J Immunother, 31(2):180-8 (2008). [cited by applicant]
Weiner, “RNA-based vaccination: sending a strong message”, Mol Ther., 21(3):506-8 (2013). [cited by applicant]
White, et al., “Role of alpha/beta interferon in Venezuelan equine encephalitis virus pathogenesis: effect of an attenuating mutation in the 5′ untranslated region”, J Virol., 75(8):3706-18 (2001). [cited by applicant]
Winslow, et al., “Suppression of lung adenocarcinoma progression by Nkx2-1”, Nature, 473(7345):101-4 (2011). [cited by applicant]
Xu, et al., “RNA replicon delivery via lipid-complexed PRINT protein particles”, Mol Pharm., 10(9):3366-74 (2013). [cited by applicant]
Yang, et al., “Surface-engineered dendrimers in gene delivery”, Chem Rev., 115:5274-5300 (2015). [cited by applicant]
Yang, et al.,“Kupfer-type immunological synapse characteristics do not predict anti-brain tumor cytolytic T-cell function in vivo”, PNAS, 107:4716-21 (2010). [cited by applicant]
Ying, et al., “Cancer therapy using a self-replicating RNA vaccine”, Nat Med., 5:823-7 (1999). [cited by applicant]
Zhang, et al. “Vaccines against Toxoplasma gondii: new developments and perspectives”, Expert Rev Vaccines, 12(11):1287-99 (2013). [cited by applicant]
Zhang, et al., “Identification and characterization of interferon-induced proteins that inhibit alphavirus replication”, J Virol, 81(20):11246-55 (2007). [cited by applicant]
Zhou, et al., “RNA melanoma vaccine: induction of antitumor immunity by human glycoprotein 100 mRNA immunization”, Hum Gene Ther, 10(16):2719-24 (1999). [cited by applicant]
Zimmer, “RNA replicons-A new approach for influenza virus immunoplylaxis”, Viruses, 2:413-34 (2010). [cited by applicant]
Ayatollahi, et al., “Synthesis of efficient gene delivery systems by grafting pegylated alkylcarbox chainsto PAMAM dendrimers: Evaluation of transfection efficiency and cytooxicity in cancerous and mesenchymal stem cell… [cited by applicant]
Sofla, et al., “Specific gene delivery mediated by poly(ethylene glycol)-grafted polyamidoamine dendrimer modified with a novel HER2-targeting nanobody” Journal of Bioactive vol. 30(2) 129-144 (2015). [cited by applicant]